Usefulness of Tumor Marker Score for Prediction of Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Multicenter Retrospective Study

Kazunari Tanaka; Kunihiko Tsuji; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hidekatsu Kuroda; Yutaka Yata; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Keisuke Yokohama; Hiroki Nishikawa; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Takashi Kumada

doi:10.20944/preprints202306.1767.v1

How to cite: Tanaka, K.; Tsuji, K.; Hiraoka, A.; Tada, T.; Hirooka, M.; Kariyama, K.; Tani, J.; Atsukawa, M.; Takaguchi, K.; Itobayashi, E.; Fukunishi, S.; Ishikawa, T.; Tajiri, K.; Ochi, H.; Toyoda, H.; Ogawa, C.; Nishimura, T.; Hatanaka, T.; Kakizaki, S.; Shimada, N.; Kawata, K.; Naganuma, A.; Kosaka, H.; Matono, T.; Kuroda, H.; Yata, Y.; Ohama, H.; Tada, F.; Nouso, K.; Morishita, A.; Tsutsui, A.; Nagano, T.; Itokawa, N.; Okubo, T.; Arai, T.; Yokohama, K.; Nishikawa, H.; Imai, M.; Koizumi, Y.; Nakamura, S.; Iijima, H.; Kaibori, M.; Hiasa, Y.; Kumada, T. Usefulness of Tumor Marker Score for Prediction of Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Multicenter Retrospective Study. Preprints 2023, 2023061767. https://doi.org/10.20944/preprints202306.1767.v1 Tanaka, K.; Tsuji, K.; Hiraoka, A.; Tada, T.; Hirooka, M.; Kariyama, K.; Tani, J.; Atsukawa, M.; Takaguchi, K.; Itobayashi, E.; Fukunishi, S.; Ishikawa, T.; Tajiri, K.; Ochi, H.; Toyoda, H.; Ogawa, C.; Nishimura, T.; Hatanaka, T.; Kakizaki, S.; Shimada, N.; Kawata, K.; Naganuma, A.; Kosaka, H.; Matono, T.; Kuroda, H.; Yata, Y.; Ohama, H.; Tada, F.; Nouso, K.; Morishita, A.; Tsutsui, A.; Nagano, T.; Itokawa, N.; Okubo, T.; Arai, T.; Yokohama, K.; Nishikawa, H.; Imai, M.; Koizumi, Y.; Nakamura, S.; Iijima, H.; Kaibori, M.; Hiasa, Y.; Kumada, T. Usefulness of Tumor Marker Score for Prediction of Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Multicenter Retrospective Study. Preprints 2023, 2023061767. https://doi.org/10.20944/preprints202306.1767.v1

Abstract

Aim: This study was to evaluate the predictive value of tumor marker (TM) score in patients with hepatocellular carcinoma (HCC) treated with Atezolizumab plus Bevacizumab (Atez/Bev) as a first-line chemotherapy. Materials/Methods: From September 2020 to December 2022, 371 HCC patients treated with Atez/Bev, in whom alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3) and des gamma-carboxy prothrombin (DCP) were measured at introducing Atez/Bev. Elevations of AFP (≥100 ng/ml), AFP-L3 (≥10%), and DCP (≥100 mAU/ml) were treated as positive, and the number of positive tumor marker was summed up and used as the previously proposed TM score. Hepatic reserve function was assessed with modified albumin-bilirubin grade (mALBI). Predictive values for prognosis were evaluated, retrospectively. Results: TM score 0 was in 81 (21.8%), score 1 in 110 (29.6%), score 2 in 112 (29.9%), and score 3 in 68 (18.3%), respectively. Median overall survival (OS) was not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA) and NA (95%CI 8.3-NA) for TM scores 0, 1, 2 and 3, respectively (p<0.001). Median progression free survival (PFS) was also 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6-21.3) and 7.7 months (95% CI 5.3-8.9), 5.8 months (95%CI 3.0-7.6), respectively (p<0.001). OS was stratified well in mALBI 1/2a as well as in mALBI 2a/2b. Whereas, PFS was well stratified in mALBI 2a/2b, while not in mALBI 1/2a. Conclusion: The TM score was a simple and useful prognostic marker in HCC patients treated with Atez/Bev.

Keywords

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Not displayed online.

Please leave your comment to this article below.

Mathematical equations can be typed in either LaTeX formats \\[ ... \\] or $$ ... $$, or MathML format <math> ... </math>. Try the LaTeX or MathML example.

Type equation:

Preview:

Copy equation into message below

Close menu

Please click a symbol to insert it into the message box below:

Please enter the link here:

Optionally, you can enter text that should appear as linked text:

Copy link into message below

Please enter or paste the URL to the image here (please only use links to jpg/jpeg, png and gif images):

Copy image into message below

Type author name or keywords to filter the list of references in this group (you can add a new citation under Bibliography):

No existing citations in Discussion Group

Wikify editor is a simple editor for wiki-style mark-up. It was written by MDPI for Sciforum in 2014. The rendering of the mark-up is based on Wiky.php with some tweaks. Rendering of mathematical equations is done with MathJax. Please send us a message for support or for reporting bugs.

Please declare any conflicts of interest you may have with this paper, financial or otherwise.

I do not have a conflict of interest

I would like to declare a conflict of interest

Display my name on the website

Captcha

Renew

I accept the following conditions:

Comments must follow the standards of professional discourse and should focus on the scientific content of the article. Insulting or offensive language, personal attacks and off-topic remarks will not be permitted. Comments must be written in English. Preprints reserves the right to remove comments without notice. Readers who post comments are obliged to declare any competing interests, financial or otherwise.

Usefulness of Tumor Marker Score for Prediction of Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Multicenter Retrospective Study

Abstract

Keywords

Subject

Comments (0)